The Combination of Ethinylestradiol/Cyproterone Acetate Is Temporarily Withdrawn from the Market in France. Is the Measure Justified?

    Nathalie Chabbert-Buffet, Jean-Jacques Amy
    Studysummary This publication discusses the political rationale behind the French regulator ANSM's decision to withdraw Diane®-35 from the market, in response to health concerns associated with third-generation oral contraceptives.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on tandfonline.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Venous and Pulmonary Thromboembolism and Combined Hormonal Contraceptives: Systematic Review and Meta-Analysis The European Journal of Contraception & Reproductive Health Care · 2012
    2. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline The Journal of Clinical Endocrinology & Metabolism · 2008